Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

Diel, Ingo J.

doi:10.1007/s00520-007-0244-9

Cited by 34 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are at least three randomized studies that substantiate the significant and sustained pain relief afforded by zoledronic acid, and one study also improved quality of life. 71 Furthermore, a Phase II study has demonstrated the feasibility of using zoledronic acid as a second-line agent for patients who have failed on pamidronate or clodronate. 85 Ibandronate is probably the best studied in the bone pain literature, having utilized the European Organisation for Research and Treatment of Cancer QLQ-C30 quality of life questionnaire, pain scale (0-4) and analgesia consumption questionnaire (0-5) in all three studies (two oral and one intravenous).…”

Section: Managing Bone Pain As An Established Skeletal Related Complimentioning

confidence: 99%

Optimal management of bone metastases in breast cancer patients

Wong

Pavlakis

2011

BCTT

View full text Add to dashboard Cite

Bone metastasis in breast cancer is a significant clinical problem. It not only indicates incurable disease with a guarded prognosis, but is also associated with skeletal-related morbidities including bone pain, pathological fractures, spinal cord compression, and hypercalcemia. In recent years, the mechanism of bone metastasis has been further elucidated. Bone metastasis involves a vicious cycle of close interaction between the tumor and the bone microenvironment. In patients with bone metastases, the goal of management is to prevent further skeletal-related events, manage complications, reduce bone pain, and improve quality of life. Bisphosphonates are a proven therapy for the above indications. Recently, a drug of a different class, the RANK ligand antibody, denosumab, has been shown to reduce skeletal-related events more than the bisphosphonate, zoledronic acid. Other strategies of clinical value may include surgery, radiotherapy, radiopharmaceuticals, and, of course, effective systemic therapy. In early breast cancer, bisphosphonates may have an antitumor effect and prevent both bone and non-bone metastases. Whilst two important Phase III trials with conflicting results have led to controversy in this topic, final results from these and other key Phase III trials must still be awaited before a firm conclusion can be drawn about the use of bisphosphonates in this setting. Advances in bone markers, predictive biomarkers, multi-imaging modalities, and the introduction of novel agents have ushered in a new era of proactive management for bone metastases in breast cancer.

show abstract

Section: Managing Bone Pain As An Established Skeletal Related Complimentioning

confidence: 99%

Optimal management of bone metastases in breast cancer patients

Wong

Pavlakis

2011

BCTT

View full text Add to dashboard Cite

show abstract

“…In the community elderly population, 20% to 50% experience pain, and the increased incidence of unrelieved pain has been shown to correlate with a decrease in mobility and functional status [6]. Because pain assessment has been an endpoint in many clinical trials examining the use of bisphosphonates, the general correlation between incidence of pain and decrease in HRQOL suggests that bone pain metrics may be used as a surrogate for HRQOL in patients with bone metastases [24]. The most commonly used pain assessments in the bisphosphonate trials were the BPI and VAS.…”

Section: Bone Painmentioning

confidence: 99%

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Costa

Badı́a²,

Chow

et al. 2008

Support Care Cancer

182

136

View full text Add to dashboard Cite

Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.

show abstract

“…They have also been shown to be effective in reducing skeletal pain [47, 60,61] and maintaining or even improving the quality of life of treated patients [60,62,63].…”

Section: Solitary or Oligometastasesmentioning

confidence: 99%

Management of bone metastases: recent advances and current status

Dennis¹,

Vassiliou²,

Balboni³

et al. 2012

J Radiat Oncol

View full text Add to dashboard Cite

This narrative review summarizes new and existing local and systemic management strategies for bone metastases from the fields of radiation oncology, medical oncology and orthopaedic surgery. Local management strategies are organized according to different clinical scenarios, with complicated bone metastases defined as those with associated pathological fractures, soft tissue components or those compressing the spinal cord or cauda equina, and uncomplicated lesions defined as those without these adverse features. The distinction applies for both sclerotic and lytic lesions. Systemic strategies are organized according to classes of therapeutic agents.

show abstract

Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

Abstract: Moreover, new treatment schedules using high dose bisphosphonates can offer rapid relief of acute, severe bone pain.

Cited by 34 publications

References 31 publications

Optimal management of bone metastases in breast cancer patients

Optimal management of bone metastases in breast cancer patients

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Management of bone metastases: recent advances and current status

Contact Info

Product

Resources

About